Jasper Therapeutics, Inc.
jaspertx.comWhat Do They Do?
Develops briquilimab, an antibody therapy targeting mast cells, for patients with chronic urticaria, asthma and other mast cell-driven diseases.
10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic…View ↗
Our lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (“SCF”) from binding to and signaling…View ↗
We are focused on advancing Briquilimab in development as a chronic therapy in mast cell driven diseases such as CSU, CIndU, asthma and…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 30, 2026
How Are They Changing?
-
Jul 17, 2026
Acquired Kira Pharmaceuticals
Sources
8-K, filed Jul 17, 2026
On July 16, 2026, Jasper Therapeutics, Inc., a Delaware corporation (the “Company” or “Jasper”), acquired Kira Pharmaceuticals (“Kira”), a…View ↗
Narrowed focus
The earlier report described programs in mast cell diseases alongside stem cell disorders, transplant conditioning and engineered stem cells. The latest report says those programs were discontinued and Jasper is focused exclusively on mast cell-driven diseases.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biotechnology company dedicated to enabling cures through therapeutics targeting mast and hemopoietic stem cells.…View ↗
Our drug development pipeline includes multiple product candidates designed to target mast and/or hematopoietic stem cells. Our lead…View ↗
Our lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (“SCF”) from binding to and signaling…View ↗
Our mRNA stem cell platform is designed to overcome key limitations of stem cell transplant and stem cell gene therapy. By using mRNA…View ↗
Who Do They Compete With?
Competes with Celldex Therapeutics, Blueprint Medicines, Novartis, Sanofi Aventis, and Evommune
10-K for FY2025, filed Mar 30, 2026Celldex Therapeutics, Inc., which is developing an antibody to KIT that is being studied in mast cell diseases;View ↗
Loading...
